Coeliac disease: boosting research efforts

The independent charity Coeliac UK has launched a research fund and accompanying fundraising appeal, which aims to raise £5 million to change the future for people with coeliac disease and gluten-related autoimmune conditions. It will boost research efforts into key areas identified and agreed by patients, carers and healthcare professionals.

With the charity celebrating its 50th anniversary this year, there is a greater urgency to find better answers to the disease, which has links to other autoimmune conditions such as type 1 diabetes and autoimmune thyroid disease, and still relies on the gluten-free diet as its only treatment.

Sarah Sleet, chief executive of Coeliac UK, said: “It is possible through further research, that finding the answers to coeliac disease could enable answers to other devastating autoimmune conditions such as type 1 diabetes. With more people being diagnosed with coeliac disease each year and with new health complications emerging, it is critical that we make the commitment now to change the status quo and make coeliac disease research everyone’s priority.”

A video was produced as part of the appeal launch to show the impact of the disease on those affected. The video, which can be accessed via the link below, shows the various presentations of coeliac disease including refractory coeliac disease type 2 (which is not responsive to the gluten-free diet), osteoporosis and gluten ataxia.

www.coeliac.org.uk/researchfund

 

Other news

Upcoming Events

HUCBMS 2019

Technological University Dublin
3-4 September 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Lab Innovations

NEC, Birmingham (Hall 12)
30 & 31 October 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Jun 2019

Recent advances in cancer diagnostics

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.